In patients with acute myocardial infarction, diabetes was associated with a non-significant increase in long-term all-cause mortality (HR 1.20) compared to non-diabetic patients.
Cohort (n=3,021)
Yes
Does diabetes worsen long-term prognosis in AMI patients, and do acute revascularization and standard pharmacotherapy improve outcomes in diabetic AMI patients?
In patients with AMI, diabetes is associated with a higher risk of long-term cardiovascular events, but acute revascularization and standard secondary prevention therapies (aspirin, RAS inhibitors) significantly improve their prognosis.
Effect estimate: HR 1.20 (95% CI 0.97-1.49)
Absolute Event Rate: 15.4% vs 11.6%
p-value: p=0.09
BACKGROUND: The long-term prognosis of diabetic patients with acute myocardial infarction (AMI) treated by acute revascularization is uncertain, and the optimal pharmacotherapy for such cases has not been fully evaluated. METHODS: To elucidate the long-term prognosis and prognostic factors in diabetic patients with AMI, a prospective, cohort study involving 3021 consecutive AMI patients was conducted. All patients discharged alive from hospital were followed to monitor their prognosis every year. The primary endpoint of the study was all-cause mortality, and the secondary endpoint was the occurrence of major cardiovascular events. To elucidate the effect of various factors on the long-term prognosis of AMI patients with diabetes, the patients were divided into two groups matched by propensity scores and analyzed retrospectively. RESULTS: Diabetes was diagnosed in 1102 patients (36.5%). During the index hospitalization, coronary angioplasty and coronary thrombolysis were performed in 58.1% and 16.3% of patients, respectively. In-hospital mortality of diabetic patients with AMI was comparable to that of non-diabetic AMI patients (9.2% and 9.3%, respectively). In total, 2736 patients (90.6%) were discharged alive and followed for a median of 4.2 years (follow-up rate, 96.0%). The long-term survival rate was worse in the diabetic group than in the non-diabetic group, but not significantly different (hazard ratio, 1.20 0.97-1.49, p = 0.09). On the other hand, AMI patients with diabetes showed a significantly higher incidence of cardiovascular events than the non-diabetic group (1.40 1.20-1.64, p < 0.0001). Multivariate analysis revealed that three factors were significantly associated with favorable late outcomes in diabetic AMI patients: acute revascularization (HR, 0.62); prescribing aspirin (HR, 0.27); and prescribing renin-angiotensin system (RAS) inhibitors (HR, 0.53). There was no significant correlation between late outcome and prescription of beta-blockers (HR, 0.97) or calcium channel blockers (HR, 1.27). Although standard Japanese-approved doses of statins were associated with favorable outcome in AMI patients with diabetes, this was not statistically significant (0.67 0.39-1.06, p = 0.11). CONCLUSIONS: Although diabetic patients with AMI have more frequent adverse events than non-diabetic patients with AMI, the present results suggest that acute revascularization and standard therapy with aspirin and RAS inhibitors may improve their prognosis.
Takara et al. (2010) conducted a cohort in Acute myocardial infarction (n=3,021). Diabetes mellitus vs. No diabetes was evaluated on All-cause mortality (HR 1.20, 95% CI 0.97-1.49, p=0.09). In patients with acute myocardial infarction, diabetes was associated with a non-significant increase in long-term all-cause mortality (HR 1.20) compared to non-diabetic patients.